Gabriel N. Hortobagyi

Oncology

1515 Holcombe Blvd Unit 1354
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 327 publications

Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).

Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).

Journal: Journal of the National Cancer Institute

Published: February 06, 2026

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 25, 2026

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.

Journal: JAMA oncology

Published: December 11, 2025

Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.

Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.

Journal: JNCI cancer spectrum

Published: October 20, 2025

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.

Journal: JAMA oncology

Published: September 25, 2025

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

Journal: ESMO open

Published: September 18, 2025

Novel Postneoadjuvant Prognostic Breast Cancer Staging System.

Novel Postneoadjuvant Prognostic Breast Cancer Staging System.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 11, 2025

Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis.

Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 19, 2025

ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.

ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.

Journal: Cancer letters

Published: December 09, 2024

Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.

Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 02, 2024

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.

Journal: JAMA oncology

Published: September 12, 2024

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.

Journal: Journal of the National Cancer Institute

Published: August 22, 2024

Showing 1-12 of 327

Last Updated: 09/26/2026